2-amino-bicyclo[3.1.0] hexane-2, 6-dicarboxylic ester derivative
    51.
    发明授权
    2-amino-bicyclo[3.1.0] hexane-2, 6-dicarboxylic ester derivative 失效
    2-氨基 - 双环[3.1.0]己烷-2,6-二羧酸酯衍生物

    公开(公告)号:US08350060B2

    公开(公告)日:2013-01-08

    申请号:US13227942

    申请日:2011-09-08

    IPC分类号: C07D307/87 A61K31/34

    CPC分类号: C07C229/50 C07D307/88

    摘要: A drug effective for the treatment and prevention of psychiatric disorders such as schizophrenia, anxiety and related ailments thereof, depression, bipolar disorder and epilepsy. The drug antagonizes the action of group II metabotropic glutamate receptors and shows high activity in oral administrationA 2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative represented by formula [I] [wherein R1 and R2 are identical or different, and each represents a hydrogen atom, a C1-10alkyl group or the like; X represents a hydrogen atom or a fluorine atom; Y represents —OCHR3R4 or the like (wherein R3 and R4 are identical or different, and each represents a hydrogen atom, a C1-10alkyl group or the like; and n represents integer 1 or 2)], a pharmaceutically acceptable salt thereof or a hydrate thereof.

    摘要翻译: 一种有效治疗和预防精神疾病如精神分裂症,焦虑及其相关疾病,抑郁症,双相情感障碍和癫痫的药物。 该药物拮抗II型代谢型谷氨酸受体的作用,并且在口服给药中表现出高活性。由式[I]表示的2-氨基 - 双环[3.1.0]己烷-2,6-二羧酸酯衍生物[其中R1和R2为 相同或不同,并且各自表示氢原子,C 1-10烷基等; X表示氢原子或氟原子; Y表示-OCHR 3 R 4等(其中R 3和R 4相同或不同,并且各自表示氢原子,C 1-10烷基等; n表示1或2的整数)],其药学上可接受的盐或 水合物。

    2-amino-bicyclo (3.1.0) hexane-2,6-dicarboxylic ester derivative
    52.
    发明授权
    2-amino-bicyclo (3.1.0) hexane-2,6-dicarboxylic ester derivative 失效
    2-氨基 - 双环(3.1.0)己烷-2,6-二羧酸酯衍生物

    公开(公告)号:US08039647B2

    公开(公告)日:2011-10-18

    申请号:US12511482

    申请日:2009-07-29

    IPC分类号: C07D317/08

    CPC分类号: C07C229/50 C07D307/88

    摘要: A drug effective for the treatment and prevention of psychiatric disorders such as schizophrenia, anxiety and related ailments thereof, depression, bipolar disorder and epilepsy. The drug antagonizes the action of group II metabotropic glutamate receptors and shows high activity in oral administrationA 2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative represented by formula [I] [wherein R1 and R2 are identical or different, and each represents a hydrogen atom, a C1-10alkyl group or the like; X represents a hydrogen atom or a fluorine atom; Y represents —OCHR3R4 or the like (wherein R3 and R4 are identical or different, and each represents a hydrogen atom, a C1-10alkyl group or the like; and n represents integer 1 or 2)], a pharmaceutically acceptable salt thereof or a hydrate thereof.

    摘要翻译: 一种有效治疗和预防精神疾病如精神分裂症,焦虑及其相关疾病,抑郁症,双相情感障碍和癫痫的药物。 该药物拮抗II型代谢型谷氨酸受体的作用,并且在口服给药中表现出高活性。由式[I]表示的2-氨基 - 双环[3.1.0]己烷-2,6-二羧酸酯衍生物[其中R1和R2为 相同或不同,并且各自表示氢原子,C 1-10烷基等; X表示氢原子或氟原子; Y表示-OCHR 3 R 4等(其中R 3和R 4相同或不同,各自表示氢原子,C 1-10烷基等; n表示1或2的整数)],其药学上可接受的盐或 水合物。

    2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative
    53.
    发明申请
    2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative 失效
    2-氨基二环[3.1.0]己烷-2,6-二羧酸酯衍生物

    公开(公告)号:US20070021394A1

    公开(公告)日:2007-01-25

    申请号:US10562018

    申请日:2004-06-25

    CPC分类号: C07C229/50 C07D307/88

    摘要: A drug effective for the treatment and prevention of psychiatric disorders such as schizophrenia, anxiety and related ailments thereof, depression, bipolar disorder and epilepsy. The drug antagonizes the action of group II metabotropic glutamate receptors and shows high activity in oral administraiton A 2-amino-bicyclo[3.1.0] hexane-2,6-dicarboxylic ester derivative represented by formula [I] [wherein R1 and R2 are identical or different, and each represents a hydrogen atom, a C1-10alkyl group or the like; X represents a hydrogen atom or a fluorine atom; Y represents —OCHR3R4 or the like (wherein R3 and R4 are identical or different, and each represents a hydrogen atom, a C1-10alkyl group or the like; and n represents integer 1 or 2)], a pharmaceutically acceptable salt thereof or a hydrate thereof.

    摘要翻译: 一种有效治疗和预防精神疾病如精神分裂症,焦虑及其相关疾病,抑郁症,双相情感障碍和癫痫的药物。 该药物拮抗II型代谢型谷氨酸受体的作用,并且在口服给药中显示高活性的由式​​[I]表示的2-氨基 - 双环[3.1.0]己烷-2,6-二羧酸酯衍生物[其中R“ 1和R 2相同或不同,各自表示氢原子,C 1-10烷基等; X表示氢原子或氟原子; Y表示-OCHR 3 R 4等(其中R 3和R 4)相同或不同, 并且各自表示氢原子,C 1-10烷基等; n表示整数1或2)],其药学上可接受的盐或其水合物。

    Intermediates and process for producing fluorine-containing amino acid compound by using the same
    55.
    发明授权
    Intermediates and process for producing fluorine-containing amino acid compound by using the same 有权
    中间体及使用它们的含氟氨基酸化合物的制造方法

    公开(公告)号:US06392086B1

    公开(公告)日:2002-05-21

    申请号:US09857631

    申请日:2001-06-07

    IPC分类号: C07C6974

    摘要: The present inventions relate to a (1S,5R,6S)- or (1SR, 5RS, 6SR)-3-fluoro-2-oxobicyclo[3.1.0]hex-3-ene-6-carboxylic acid derivative represented by Formula (1): [in the formula, R represents OR1 or NR1R2, wherein R1 and R2 are identical or different, and each represents a hydrogen atom, a C1-C6 alkyl group, a C3-C6 cycloalkyl group, a (C3-C6 cycloalkyl) (C1-C6 alkyl) group, an aryl group, an aryl (C1-C6 alkyl) group, a (C1-C6 alkoxy) (C1-C6 alkyl) group, a C1-C6 hydroxyalkyl group, a (C1-C6 alkylthio) (C1-C6 alkyl) group, or a C1-C6 mercaptoalkyl group], and a process for producing the same, and a process for efficiently producing a fluorine-containing amino acid compound acting on group 2 metabotropic glutamate receptors, which has treatment effects or prevention effects on psychiatric diseases or neurological diseases, characterized by hydrogenating the derivative, and subsequently, subjecting it to hydantoination or aminocyanidation, followed by hydrolysis.

    摘要翻译: 本发明涉及式(1S,5R,6S) - 或(1SR,5RS,6SR)-3-氟-2-氧代双环[3.1.0]己-3-烯-6-羧酸衍生物 1):[式中,R表示OR 1或NR 1 R 2,其中R 1和R 2相同或不同,表示氢原子,C1-C6烷基,C3-C6环烷基,(C3-C6环烷基) )(C1-C6烷基),芳基(C1-C6烷基),(C1-C6烷氧基)(C1-C6烷基),C1-C6羟基烷基,(C1-C6烷基) 烷基硫基)(C1-C6烷基)或C1-C6巯基烷基]及其制备方法,以及有效地制备作用于第2族代谢型谷氨酸受体的含氟氨基酸化合物的方法,其具有 治疗效果或预防对精神疾病或神经系统疾病的影响,其特征在于使该衍生物氢化,然后使其进行乙烯基化或氨基化,然后进行水解。

    Fluorine-containing amino acid derivatives
    56.
    发明授权
    Fluorine-containing amino acid derivatives 有权
    含氟氨基酸衍生物

    公开(公告)号:US06316498B1

    公开(公告)日:2001-11-13

    申请号:US09601131

    申请日:2000-07-27

    IPC分类号: C07C6974

    CPC分类号: C07C229/50 C07C2602/18

    摘要: Fluorine-containing amino acid derivatives represented general formula (I), pharmaceutically acceptable salts thereof or hydrates of the same, wherein X1 represents hydrogen or fluorine; and R1 and R2 are the same or different and each represents hydrogen or lower C1-10 alkyl. These compounds are useful as drugs, in particular, group 2 metabotropic glutamate receptor agonists for treating and preventing psychiatric disorders such as schizophrenia, anxiety and associated diseases, depression, bipolar disturbance and epilepsy, and neurological diseases such as drug addiction, cognition disorder, Alzheimer's disease, Huntington's chorea, Parkinson's disease, motility disturbance associating muscular stiffness, cerebral ischemia, cerebral insufficiency, spinal cord lesion and head disturbance.

    摘要翻译: 含氟氨基酸衍生物表示通式(I),其药学上可接受的盐或其水合物,其中X1表示氢或氟; 并且R 1和R 2相同或不同,各自表示氢或低级C 1-10烷基。 这些化合物可用作药物,特别是用于治疗和预防精神疾病如精神分裂症,焦虑和相关疾病,抑郁症,双相障碍和癫痫以及神经系统疾病如药物成瘾,认知障碍,阿尔茨海默氏症的药物,特别是第2代代谢型谷氨酸受体激动剂 疾病,亨廷顿氏舞蹈病,帕金森病,运动障碍,肌肉僵硬,脑缺血,脑功能不全,脊髓损伤和头部干扰。

    2-carbonylthiazole derivatives and use of the same
    57.
    发明授权
    2-carbonylthiazole derivatives and use of the same 失效
    2-羰基噻唑衍生物及其用途

    公开(公告)号:US6166033A

    公开(公告)日:2000-12-26

    申请号:US269021

    申请日:1999-11-05

    CPC分类号: C07D417/06

    摘要: This invention provides a 2-carbonylthiazole derivative represented by formula (I): ##STR1## wherein each of Ar.sup.1 and Ar.sup.2 represents a phenyl group or a substituted phenyl group; R.sup.1 represents an alkoxy group having 1 to 5 carbon atoms, a hydroxyl group or an amino group; Y.sup.1 --Y.sup.2 represents CH--CO or C.dbd.CR.sup.2, wherein R.sup.2 represents a hydrogen atom or an alkyl group having 1 to 5 carbon atoms; and n is an integer of from 1 to 4, or a pharmaceutically acceptable salt thereof. The disclosed compounds are useful as drugs for preventing and treating dopamine D receptor-related morbid states such as schizophrenia and problematic behavior caused by cerebrovascular accidents and senile dementia and do not induce extrapyramidal disorders as side effects.

    摘要翻译: PCT No.PCT / JP97 / 03342 Sec。 371日期1999年11月5日 102(e)1999年11月5日PCT PCT 1997年9月19日PCT公布。 公开号WO98 / 12195 日期:1998年3月26日本发明提供由式(I)表示的2-羰基噻唑衍生物:其中Ar1和Ar2各自表示苯基或取代的苯基; R1表示碳原子数1〜5的烷氧基,羟基或氨基。 Y1-Y2表示CH-CO或C = CR2,其中R2表示氢原子或具有1至5个碳原子的烷基; 和n为1〜4的整数,或其药学上可接受的盐。 所公开的化合物可用作预防和治疗多巴胺D受体相关的病态,如精神分裂症和由脑血管意外和老年痴呆引起的问题行为的药物,并且不诱导锥体外系疾病作为副作用。

    Aminoalkylthiazole derivative
    58.
    发明授权
    Aminoalkylthiazole derivative 失效
    氨基烷基噻唑衍生物

    公开(公告)号:US5502202A

    公开(公告)日:1996-03-26

    申请号:US142471

    申请日:1993-11-29

    IPC分类号: C07D277/40

    CPC分类号: C07D277/40

    摘要: Object: To provide an antipsychotic drug being different in functional mechanism from dopamine autoreceptor agonists, namely, to provide an antipsychotic drug having a specific affinity for a sigma receptor and causing no extrapyramidal disorder.Constitution: An aminoalkylthiazole derivative represented by formula: ##STR1## (wherein R.sup.1 represents a phenyl group substituted with a halogen atom; R.sup.2 and R.sup.3 are either the same or different and each represents an alkyl group having 4 to 10 carbon atoms; and n is 2 or 3;) and a salt thereof.

    摘要翻译: PCT No.PCT / JP92 / 00702 Sec。 371日期:1993年11月29日 102(e)日期1993年11月29日PCT提交1992年5月29日PCT公布。 出版物WO92 / 21667 日期1992年12月10日。对象:提供与多巴胺自身受体激动剂不同功能机制的抗精神病药物,即提供对σ受体具有特异性亲和力并且不引起锥体外系疾病的抗精神病药物。 结构:由下式表示的氨基烷基噻唑衍生物:其中R1表示被卤素原子取代的苯基; R2和R3相同或不同,表示碳原子数4〜10的烷基,n表示 2或3;)及其盐。

    Alkoxyphenylalkylamine derivatives
    59.
    发明授权
    Alkoxyphenylalkylamine derivatives 失效
    烷氧基苯基烷基胺衍生物

    公开(公告)号:US5495046A

    公开(公告)日:1996-02-27

    申请号:US211449

    申请日:1994-03-31

    摘要: An alkoxyphenylalkylamine derivative represented by the following formula: ##STR1## (wherein X.sup.1 and X.sup.2 may be either the same or different from each other and each represents a hydrogen atom, a halogen atom, a hydroxyl group, an alkoxy group having 1 to 5 carbon atoms or an alkoxy group having 1 to 5 carbon atoms and substituted with a phenyl group; R.sup.1 and R.sup.2 may be either the same or different from each other and each represents a hydrogen atom, an alkyl group having 1 to 7 carbon atoms, an alkyl group having 1 to 7 carbon atoms and substituted with "a hydroxyl group, a carboxyl group or an alkoxycarbonyl group" at the end, or, R.sup.1 and R.sup.2 together with the adjacent nitrogen atom represent a pyrrolidino group, a piperidino group or a piperadino group, all of which may be optionally substituted; A represents a phenyl group, a phenyl group substituted with 1 to 3 substituents arbitrarily selected from "a halogen atom, a hydroxyl group and an alkoxy group having 1 to 5 carbon atoms" or a thienyl group; m is an integer of from 2 to 5; and n is an integer of from 2 to 7), and a salt thereof.

    摘要翻译: PCT No.PCT / JP92 / 01259 Sec。 371日期1994年3月31日 102(e)1994年3月31日PCT提交1992年9月30日PCT公布。 公开号WO93 / 07113 日期:1993年4月15日。下式表示的烷氧基苯基烷基胺衍生物:其中X 1和X 2可以相同或不同,各自表示氢原子,卤素原子,羟基, 具有1至5个碳原子的烷氧基或具有1至5个碳原子并被苯基取代的烷氧基; R 1和R 2可以相同或不同,各自表示氢原子,具有1个 至7个碳原子,碳原子数为1〜7的烷基末端被“羟基,羧基或烷氧基羰基”取代,R1,R2与相邻氮原子一起代表吡咯烷子基, 哌啶子基或哌啶子基,其全部可以被任选取代; A表示苯基,被1〜3个选自“卤素原子,羟基和1〜5的烷氧基的任意取代基”所取代的苯基 ca 原子“或噻吩基; m为2〜5的整数; 和n为2〜7的整数)及其盐。

    Carbazole compounds
    60.
    发明授权
    Carbazole compounds 失效
    卡博唑化合物

    公开(公告)号:US5116995A

    公开(公告)日:1992-05-26

    申请号:US702507

    申请日:1991-05-20

    IPC分类号: C07D209/86

    CPC分类号: C07D209/86

    摘要: Carbazole compounds represented by the formula ##STR1## wherein R.sup.1 is a hydrogen atom or an alkyl group having 1 to 5 carbon atoms, R.sup.2 is a hydrogen atom, an alkyl group having 1 to 5 carbon atoms, an alkanoyl group having 2 to 6 carbon atoms or a benzoyl group, R.sup.3 and R.sup.4 are the same or different, and are each hydrogen atom, an alkyl group having 1 to 7 carbon atoms, an alkenyl group having 2 to 4 carbon atoms, an alkyl group having 1 to 3 carbon atoms substituted by a phenyl group, or R.sup.3 and R.sup.4 together with the nitrogen atom to which they are attached form a morpholino group, a piperidino group, a pyrrolidino group or a piperazino group, and n is an integer from 1 to 3, and salts thereof have strong antipsychotic activity.